Advances in bioavailability. Innovations in delivery technologies and dose forms. Proven results from our team of scientists, researchers, and regulatory experts.
Catalent and Kappa Bioscience have partnered to develop an innovative nutritional supplement for heart health. Introducing Cardio K2 Double Strength...
How can decisions made during the preclinical phase of drug development increase the chances of a product’s eventual success in a difficult marketplace?
As pharmaceutical companies have grown larger to offer a broader range of products and services, the key challenge is to connect experts around the globe and to leverage...
The USP general chapter <1207> “Package Integrity Evaluation – Sterile Product” deeply changes the way it considers the Container Closure Integrity Testing (CCIT) within the pharmaceutical industry.
Given the accelerated timelines associated with expedited programs, lipid-based drug formulations, encapsulated in softgel capsules, provide an attractive option for addressing the challenges facing formulators.
An early-phase formulation strategy for poorly soluble molecules is essential for overcoming potential challenges in...
This document provides an overview of the capabilities of the Catalent Inhalation business across both our Morrisville/RTP, NC and Woodstock, IL sites.
The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research.
Changes during purification, formulation, fill-finish, and distribution can affect protein stability and practically all steps in the manufacturing process may perturb the...
Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions
Biopharmaceutical products in development continue to increase in complexity. These include numerous multi-specific...
Technology transfer is a challenging and multi-faceted endeavor, with multiple variables that must be carefully considered.
It is vital that drug products reach patients uncontaminated and unadulterated by their packaging.
To be successful, new treatments require real-world outcomes for you, your stakeholders, and most importantly the patients.
There are multiple opportunities for companies to speed time to clinic, which impacts the speed to market. Processes such as dose form development and clinical trial planning can be started earlier to reduce issues and delays.
Clinical trials are conducted according to a protocol, which is the master action plan for how the study will be conducted.
Testing for elemental impurities in pharmaceuticals is a key risk assessment activity. This eBook published by Pharmaceutical Technology provides an overview...
Get latest insights on the key trends that are contributing to the uptick in omega-3s sales including new raw material sources, concentrated oils, emerging market and new products and delivery systems.
Free trade zones (FTZ) in China provide clinical sponsors with specially designated areas to receive materials produced outside of China for the packaging, storage, and distribution of clinical supplies to studies in China and beyond.
Biologic drug development is complex, requiring broad capabilities and expertise to ensure the highest likelihood of regulatory approval and commercial success.
Shortening timelines to generate more productive, stable and high expressing cell lines is the goal of any cell line development program.
The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.
Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.
Learn about the latest blow-fill-seal solutions, from development through commercial-scale manufacture.
A new wave of biologics in the clinic has forced companies to rethink how they execute Phase I studies.
Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization.
Lipid formulation and spray-dried dispersions are widely used, and proven technologies to overcome bioavailability challenges for poorly soluble molecules.
There are many challenges to conduct thorough drug product formulation development at early stage drug substance process development.
We will review the current OTC remedies for cough, cold and allergy categories and discuss strategies to grow your share on shelf space with innovative dosage forms.
Watch this webinar to learn the key considerations for evaluating available technologies to find the most suitable bioavailability solution.
Read this article published by Pharmaceutical technology to learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.
Read the latest article published by Pharmaceutical Technology giving an overview of elemental impurities testing and elemental impurities risk assessment process.
The 3M™ Emphaze™ AEX Hybrid Purifier is a novel purification tool that utilizes a Q-functional hydrogel and 0.2 μm membrane to reduce impurities in a biopharmaceutical downstream process.
Watch the webinar to learn about a range of new market-ready formulations to create vitamin K2 supplements and gain market share.
During this Q&A, Dr. Jun Lu, Director discusses how Catalent utilizes automation, specifically the UNcle® platform*, during formulation development.
Catalent Biologics provides comprehensive services to meet complex biologic development needs. Click to see our global locations and services.
This webinar details a product, wherever it is in its lifecycle, and how consistency, planning and communication form the building blocks for success in the manufacturing process transfer.
Watch the webinar to get expert insights on the applications of analytical techniques to help answer various questions during the product development process
Download the article to learn about stability strategy for clinical trials, the importance of supply chain communication, automated control systems and country-specific labeling protocols.
Unique combo formula containing LONGVIDA® Curcumin Extract intended to support joint comfort
Unique combo formula with LUTEMAX® 2020 & DHA ORIGINS™ 550 Algal Oil intended to help protect the eyes from blue light
Understand why new therapies fail or succeed in the market place and learn when and how to apply advanced technologies to help increase the chance of success
Catalent Biologics' two state-of-the-art facilities have been designed to provide integrated bulk drug substance for clinical trials and commercial launches.
View this infographic to discover how Catalent can help you differentiate your nutritional supplement brand, gain a competitive edge, and get more products to market faster!
How Catalent’s formulation development and manufacturing expertise helped a topical skincare company to successfully launch a brand new ingestible supplement to the global market.
Discover advanced and innovative technologies targeted to meet specific needs of older consumers.
Learn more about how marketers can launch better Omega-3 supplements using this revolutionary microemulsion technology.
This eBook explores the multitude of factors that can impact clinical supplies and techniques and strategies that clinical supply professionals can apply to keep clinical supplies off the critical path.
In this poster, scientists at Catalent Biologics propose a stepwise approach for the definition and execution of process characterization for the production of a monoclonal antibody.
In this poster, scientists at Catalent Biologics outline a method utilizing a high-throughput, micro-well plate platform to economically screen a mAb in 96 formulations.
In this poster, Catalent Biologics outlines a strategy using inductively coupled plasma-mass spectrometry (ICP-MS) to conduct trace-level multiple analysis.
Learn more about how the biomanufacturing and fill/finish markets are growing year over year.
Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (API), excipients, manufacturing equipment, and primary container closure systems.
Strategies companies can use to succeed in both advancing their candidates and attracting investors
Solid form screening and selection is an integral part of drug development.
Quality by Design (QbD) is well established in the pharmaceutical industry for manufacturing processes, including active pharmaceutical ingredients and drug products.
This article outlines the preclinical studies to assess and manage developability risks of NMEs for oral drug products
This article outlines a method for investigational new drug (IND)-enabling extended characterization for ADCs.
Roller compaction is a popular dry granulation process with some significant advantages over wet granulation processes.
How to create a development strategy that bridges gaps earlier in the process to make the transition smoother.
How to reliably bring products to market quickly without sacrificing compliance.
Watch this webinar to learn more about the Beacon(R) platform and how it can accelerate cell line development.
Watch this webinar to see an overview and case study of process characterization performed by Catalent.
In this ebook, Catalent discusses efficiencies specific to early biopharmaceutical formulation development and biomanufacturing continuous processing.
Discover a solution to ensure quantity & quality of the excipient Polysorbate-80 in drug formulations.
In this case study, Catalent compared the productivity of purifications running in batch versus continuous mode.
Considerations for Adoption and Case Studies in Biologic Development and Manufacturing
Lipid-based drug delivery systems provide a reliable solution for poorly soluble molecules
This case study outlines the steps that Catalent took to ensure the QP release process could quickly advance in Israel while simultaneously updating the warning labels to meet the QP requirements
View this webcast to learn how these consumer insights and innovative formulations can help drive your brand growth and market share.
Learn how Catalent's strategy for developing, optimizing and testing analytical cell banks.
Learn how Catalent can formulate, fill, and package your product into vial, pre-filled syringe, or cartridge injectable formats that are ready-to-use for the patient or healthcare professional.
Catalent’s packaging operations in Bloomington, IN and Brussels, Belgium offer state-of-the-art, high-speed, automated equipment as well as configurable packaging and assembly rooms.
Discover how a pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage.
Read about how key players within the market are focusing their efforts to ensure products are of the highest quality, safe, and easy to use.
Learn more about the advances in analytical techniques for biopharmaceuticals.
Characterization of the micronized drug is important to understand its bulk properties and design downstream processes and manufacturing approaches.
Read about the history and progress to date, and look at what might be preventing ADCs from reaching their full potential.
Clarifying the myths surrounding LBDSS which may make drug developers consider it in parallel to other formulation approaches
Stability is a critical quality attribute of pharmaceutical products
Developers are looking for ways to predict and overcome potential issues of new molecular entities
Current critical issues facing the oral solid dose manufacturing industry
Read this article and learn about focus areas in the early drug development process that are critical for a successful toxicology study.
Learn how protocol design can potentially impact the costs, timelines, operational complexity, and overall risk incurred when sourcing comparators.
Explore how to proactively plan for a clinical supply chain that provides greater visibility and control over clinical supplies.
Learn more about the advanced cross-action formula that targets multiple layers of the skin to blur, re-surface, plump skin lipids and moisture, repair and protect skin from the effects of aging.
Gain more knowledge on dysphagia, which is one of the major factors affecting medication adherence and proper medication administration.
Read this case study on commercial scale-up on fluid bed wurster coating.
Learn more about Wurster Process at Catalent Winchester.
Explore how Brexit may change the working relationship between Qualified Persons (QPs) in the UK and EU through a moderated Q&A roundtable.
As the biologics industry continues to grow, biopharmaceutical companies are evaluating continuous processing as a potential means to improve efficiencies.
Developing specific dosing guidelines and acceptable dosage forms for pediatric patients to optimize therapeutic efficacy and limit and prevent serious adverse side effects.
A connected, data-driven approach to managing bioavailability challenges in new chemical entities
Leveraging knowledge about an API’s physiochemical properties from preformulation and formulation studies increases the chances of early-phase success.
The key to a successful tech transfer is for the vendor and the contract manufacturer to anticipate the challenges and come up with a game plan for the solutions to potential challenges.
Developing a tailored package of analysis to ensure compliance with regulatory guidelines.
This webcast discusses key concepts that should be addressed as a molecule advances through the clinical development phases
Selecting the best risk assessment and analytical testing strategy is key to successful compliance with the new regulations.
Learn about the challenges of developing and manufacturing biologics and the specific challenges of one area of biologics innovation, antibody drug conjugates (ADCs).
Aging consumer trends, innovative formulation technologies and solutions targeted to meet the specific needs of the aging consumer.
This whitepaper is intended to help sponsors understand how the various Brexit outcome scenarios may specifically impact clinical supplies.
View webinar on how Biogen and Catalent prepare for effective automation transfers.
Watch this on demand webinar to ensure sure your clinical supply playbook is ready for Phase II and beyond.
The use of Pre-clinical tools to study pharmacokinetics, choose a lead drug candidate and move that product into development.
Understanding cold chain shipping challenges and comparing solutions for temperature-sensitive product handling.
Regulatory requirements and technical challenges for stability studies vary depending on the phase of the program, the intended market and the product type.
Identifying and verifying an unknown leachable through structural elucidation, synthesis and mass spectral confirmation.
From delays in the study timeline to budget constraints and regulatory requirements, the challenges associated with management and execution of clinical supplies are many and varied.
Applying clinical supply management expertise to overcome inventory challenges for a complex, global study.
Learn how to manage the clinical supply returns process and how Catalent helps sponsors design a more holistic strategy.
Webinar on the critical role of date, relationships, and experience in comparator sourcing success.
Learn how best practices for leveraging the resources of sourcing vendors are vital to anticipating and avoiding clinical supply delays.
Learn how the leading service providers are prepared to provide analytical and bioanalytical methods that address the growing market for complex compounds and biologics.
Get the steps involved in the development and manufacturing of an ASD via the spray drying process.
Discover the challenges posed by single-use bioreactor bags in contributing to extractables and leachables in the biomanufacturing process.
Expert insights on ODT challenges and solutions from European Pharma Manufacturing.
Insights on developing and marketing biopharmaceutical and biosimilar products worldwide.
Patented technology designed to overcome consumer challenges with Omega-3s, such as fishy burps, foul odor and aftertaste.
This webinar presents a range of innovative dosage forms specifically designed to overcome Omega-3 challenges.
Automating bioassays improves success rates and reduces manual steps.
How using an optimized approach can improve inventory management and supply chain performance.
Learn the key considerations for developing a new drug for pediatric patients.
Key insights on guidelines, testing requirements, and analytical approaches for complying with the USP requirements for instrument-based heavy metals testing.
Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase.
Tips and advice on overcoming the most common formulation mishaps and why beginning with the end in mind is crucial.
How pre-clinical work is driving rapid evaluation of how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes.
How pre-clinical tools used in the industry to study pharmacokinetics are used to guide the development of new chemical entities (NCEs).
Explore how to leverage the major clinical supply centers to support clinical trials within the Asia-Pacific region for both local and global study sponsors.
The key considerations for transitioning a molecule from discovery to Phase 1.
The logistical and regulatory challenges associated with clinical trial supply distribution can rise exponentially when certain regions of the world are included.
Learn more about cell line development, upstream process development and process scale-up for SMARTag® technology antibody programs.
Evaluate critical areas in the drug development process to help ensure a successful toxicology study.
Advanced Beauty Solutions with CosmoPod™ technology Innovative, Flexible Unit-Dose Capsules
How to apply lipid based formulation and encapsulate in softgel capsules for a poorly soluble molecule.
A review and quantitative analysis of the molecular properties of approved drugs formulated as lipid systems
Learn how the growing need for partners who can provide niche technologies to accelerate development projects.
With our diverse range of parenteral delivery platforms, we create tailored solutions for your most difficult challenges.
Unique biologics solutions and technologies to help develop market-leading products.
The key spray dried dispersion (SDD) development considerations to enhance and sustain in-vivo drug solubility.
The key spray dried dispersion (SDD) development considerations to enhance and sustain in-vivo drug solubility.
A holistic approach to the development and manufacture spray dried dispersions.
Controlled and Modified Release dosage form can improve patient experience.
Each new drug is unique and deserves a fresh approach to formulation.
Utilizing forecasting throughout the clinical study to plan clinical supply budgets and timelines.
Successful spray drying process for clinical and commercial production.
Discover the variety of shapes and sizes available for Gelatin Capsules.
Discover the variety of shapes and sizes available for Vegicaps® Capsules.
Innovative packaging solution meeting the needs both patients and the clinical sites
Modern aseptic performance demands new flexibility in both mindset and technology
Key considerations for transitioning a molecule from discovery to phase 1 readiness
A proven track record of delivering more differentiated products, faster.
Introducing Catalent’s Skin Rescue CosmoPod™ Twist-Off Capsules
Customize and unique manufacturing solutions to manufacture your drug.
Unbiased & data-driven approach to select bioavailability enhancement technology.
Improve efficiency and reduce your trial timelines.
How lipid-based drug delivery systems (LBDDS) can be used as a bioavailability enhancing technology.
Scientifically designed skin care formulation to deliver Ratinol and Vitamin C for skin care.
New strategies and innovations for the evolving patient-centric clinical trials
Questions to ask your CRO better understand your clinical supply needs.
Synergistic clonal and process screen to identify master cell bank candidates
Cultural and business norms for conducting successful clinical study in APAC region.
How the industry’s most stable drug form is innovating and evolving to stay relevant.
How formulation screening early in the process can reduce development timelines.
Get the seven steps to implement a new manufacturing technology.
Identify transit strategies in emerging regions to ensure movement of clinical supplies.
Advanced formulation and drug delivery technologies for patient-centric drug design.
Agnostic & data-driven approach for early stages to find optimal formulation technology
Development of Cannabis- based drugs can offer a consistent, reliable dose with minimal side effects.
Customized Manufacturing Solutions to meet your complex manufacturing needs
Learn how to move from the bench to the clinic quickly using advanced technologies
Discover how orally disintegrating tablets (ODTs) can be both patient friendly and offer numerous formulation advantages.
How pre-formulation techniques can accelerate early phase development to animal PK and first-in-human studies.
As the Biopharma market evolves, the demand increases for bioprocess technologies.
The effect of salt form selection and polymorphic screening on formulation development.
Brand strategies to leverage innovative consumer preferred dose forms for Omega-3 market.
Innovative products and techniques to develop, scale-up, analyze and process complex biologics.
Crucial factors to transform a pre-clinical compound into a first-in-human candidate.
Learn about the new strategy model for outsourcing.
Key development challenges and promising technologies for delivering pediatric formulations.
Insight on early development, characterizing solid state forms and first-in-human strategies.
Latest formulation approaches on enabling oral route for macromolecule drugs for local treatment.
Effective outsourcing strategies and demonstrating how these can be effective through a case study.
Explore best practices for clinical trial materials logistics for different global region & more.
How novel innovations and integrated fill/finish services can bring your product faster to market.
Unique roller compaction platform designed to achieve clinical and commercial success.
Designing state-of-the-art facilities and suites address customers’ current and future needs.
Revolutionize the way vegetarian products are encapsulated.
Strategies on incorporating patient opinion into early drug design and boost patient adherence.
Technology management approach & process capabilities for reliable supply of drug products.
A guide on creating flexible and custom manufacturing solutions for speciality products.
A parallel formulation feasibility assessment approach to enhance bioavailability.
Discover new developments in ODT technology including delivery of peptides and vaccines.
Explore the most-read articles from 2016, chosen by the Pharmaceutical Manufacturing audience.
Methods for developing a sound, phase-appropriate formulation for early development.
A systematic approach to tech transfers and how to focus on technical expertise & flexibility.
Explore the latest biopharma facility investment trends.
Softgel technology for early development to achieve successful formulation and patient outcomes.
Latest softgel technology for targeted and controlled delivery of challenging molecules.
A toolkit of superior technologies to overcome all your molecule’s challenges and processing difficulties to get the optimal dosage form.
Achieve a faster assessment of monoclonal antibody functionality—well before the final molecule is selected.
Explore how orally disintegrating tablets (ODTs) provide an alternative to overcome several challenges.
Utilize OptiForm Solution Suite to provide options for candidate formulations with extensive supporting data.
Expand your offerings with Twist-Off technology for oral & topical OTC applications.
Solutions for better informed decision making and contingency planning in inherently dynamic trials.
Innovative dosage forms that are likely to succeed & create a differentiated products in an increasingly crowded market space.
Create market differentiation and enable products that meet the specific medical needs of individual patients.
Discover the latest solutions and advancement in drug delivery technologies.
Create a supply chain structure that is better suited to meeting the changing demands of today’s more complex studies.
Improve the efficiency, reliability, flexibility & speed to market for your next manufacturing process.
Innovative, integrated approach to rapidly screen biomolecules potential for oral delivery.
Biomanufacturing strategies & integrated approach on improving and de-risking lead selection.
Effectively evaluate the potential of peptides and macromolecules for oral delivery.
Strategies to drive biologics development programs & meet aggressive development timelines.
Insights on how to pick the right candidates for clinical development & revamping projects.
Enhance bioavailability & efficacy while reducing adverse effects with particle size reduction.
Discover how innovative dose forms can meet the consumers’ needs based on age & gender.
Innovative technologies to address OTC specific needs of an aging population.
Strategies & technologies which can minimize the risks of developing new drugs and more.
Better patient treatments fueled by innovations in lipid formulations.
New innovations for OTC brands creating new users, increased usage & stronger market growth.
We are helping innovators develop, deliver & supply superior products improving people’s lives.
Characterize molecules, apply right prediction model, & select ideal delivery technology.
Address the changing nature of clinical trials and the supply of materials for studies.
Innovative network strategies & supply models to support global clinical trials.
Innovative solution for overcoming encapsulation challenges for OTC products.
Efficiently and rapidly overcome complex bioavailability challenges for early stage molecules.
Discover an innovative way to deliver challenging and poorly soluble compounds.
Cell development and process scale-up for an antibody program with additional processing.
Avoid some of the limitations of conventional tablet dose forms & more.
ODT platform ideal for sublingual delivery of proteins, peptides & vaccines.
Address compounds early on in the development process to reduce costs & attrition rates.
Ensure your technology transfers meet scheduled timelines.
Strategies for oral formulation selection which can lower attrition rates and more.
Address bioavailability challenges faced in biologic development with a focus on oral delivery.
Drive greater speed, flexibility and efficiency into the clinical supply chain.
Discover new approach to optimize oral dose development for macromolecules.
Evaluate trends in emerging fields and cultural change in the clinical trials industry.
Have a rigorous and carefully designed plan as to how to handle the compounds safely.
Ensuring that the necessary supplies of patient kits are in the right place at the right time.
Enhance global supply of vaccines through primary container design & manufacturing efficiency.
Understand the logistics of commercial manufacturing using design of experiments (DOE).
Biotech advances that have revolutionized human health being adapting for veterinary use.
Help improve the lives of animals and the people who care for them.
Explores the benefits of co-micronization with a surfactant and cryogenic micronization.
Reduce complexity & drive efficiency through a hub-based approach within the APAC region.
Strategies to overcome challenges when sourcing comparator compounds for clinical trials.
New developments in ODT technology, including new ways to administer peptides & vaccines.
Differentiate products at the unit dose level & deliver a more recognizable product.
Define key aspects of product performance which must be met when developing a generic pMDI.
High potency vitamin C 20% that delivers an effective amount to the skin for best results.
Insights into the new generation of antibody drug conjugates
Integrated solutions to rapidly screen biomolecules potential for non-invasive delivery route.
Obtain consistent highly pure products, lower manufacturing costs & improve process efficiency.
Rapidly screen biomolecules’ potential for a non-invasive delivery route.
A DLS approach is an innovation needed to meet the challenges of complex clinical trials.
A proactive approach is essential for reducing the risk of supply-related delays and more.
Softgel dosage forms could increase consumer compliance and a faster onset of action.
Address development challenges early on and improve a drug’s path to market.
Address challenges in developing biologics and identify keys to succeed in this dynamic space.
Utilize ADCs as targeted therapeutics for the treatment of cancer & potentially other diseases.
Leverage solid dispersion & particle size reduction technology to enhance bioavailability.
Address the potential compatibility concerns with BFS processed container systems.
Choose a superior alternative to the traditional tablet dosage forms.
Make the right decisions to ensure a successful technology transfer.
Mitigate cross-contamination risk and regulatory issues.
Enhance the global supply of vaccines through container design & manufacturing efficiency.
Select optimal formulation technology to enhance therapeutic performance & patient experience.
Enable precise, programmable, site-selective chemical protein modifications to develop ADCs.
Expedite the development pathway for early phase compounds and enhance bioavailability.
Enhance bioavailability, deliver liquid APIs & more with softgel technology.
Utilize particle size reduction and formulation technologies to optimize the API.
Successfully manufacture oral dosage forms that disperse within 3 seconds & are enjoyable.
Unique technologies to help develop market-leading products across all beauty care categories.
Utilize local supply advantages & overcome comparator sourcing challenges for clinical studies.
Apply the right clinical supply model based on the nature of the study.
Defining the challenges with manufacturing ADCs and how the market is evolving.
Explore theories and strategies used to build successful antibody-drug conjugates designs.
Supplementing cell culture media with copper can reach high yields of highly converted protein.
Explore the challenges with delivering drugs less invasively.
Successfully develop biological therapeutics within an aggressive program timeline.
Boost bioavailability, improve ease & route of administration, and increase patient compliance.
Address unique program requirements with flexible manufacturing solutions.
Identify new technologies and research resources to navigate emerging trends.
Increase the dissolution rates of poorly water-soluble drugs to increase bioavailability.
Explore new drug development tools to optimize Animal Health products.
Utilize the right APAC packing & distribution network to start studies on time & reduce cost.
Increase patient adherence while reducing reformulation time & costs.
Develop & optimize a logical sourcing strategy in the Asia Pac Region.
Identify most suitable drug delivery technology at early stage of drug development.
Provide the ability to taste mask & coat smaller particle size APIs.
Discover the latest solutions for drug development, design, manufacturing & scale-up.
Utilize an all-encompassing approach to enable an effective dosage form faster to market.
Single unit granule formulation allows for high drug load & broad taste-masking techniques.
Implement QbD for inhalation product development to ensure drug and device efficacy and safety.
Enable the formulation development of a drug molecule in softgels on industrial scale machines.
Determine the best clinical supply model to reduce risk and improve performance.
Improve product performance & enhance consumer experience with enteric coating.
Meet the high demands of all natural products with innovative dosage form solutions.
Increase chances of success in drug development by focusing on API optimization from the start.
Successfully launch & develop specific requirements for small molecules, like Safinamide.
Suitable path to accelerate development, avoid risk at early phase & enhance bioavailability.
The rise of Krill Oil education, versatile benefits and consumer acceptance.
Successfully complete multiregional clinical trials (MRCT).
Prevent, treat or manage existing conditions to improve aging consumer's quality of life.
Select the most suitable formulation technology to enhance the molecule’s bioavailability.
The future of non-invasive delivery technologies for large molecules.
Deliver products successfully & economically to emerging markets.
Overcome therapeutic challenges and be prepared for years to come.
Manage a Clinical Supply Chain that is flexibe, traceable, & compliant.
Mitigate risk and drive towards safe and effective drug manufacturing.
Overcome ADC development challenges & improve efficacy and safety.
Generate physically stable & processable amorphous forms of APIs.
Transition from preliminary formulation to commercial drug launch, quickly & cost-effectively.
Unique Consumer Health solutions for OTC, Supplements & Beauty.
Deliver more differentiated dietary supplement products, faster to market.
Strategies and tactics to develop new antibody biosmilar products.
Oral dose development with optimal therapeutic performance.
Ideal solution for consumers seeking an animalfree alternative to gelatin capsules.
Develop liquid capsule fill formulations that are mitigated to prevent abuse.
Limit individual variability of type I & II systems with adequate choice of composition.
Handle small amounts of API or formulation at the early stages of development.
Reduce the potential for iatrogenic transmission of pathogenic viruses.
Design a safe, effective & stable dosage form, and ensure patient compliance.
Successfully achieve taste-masking while maintaining release characteristics.
Develop oral dosage forms of water-insoluble compounds with amorphous solid dispersions.
Monitor crystalline state of a compound during stability studies.
Incorporate high concentrations of various oils in an ODT.
Integrated, tailored solutions to accelerate your path to market.
Enable expanded biotechnology applications of the aldehyde tag.
Reduce the risks associated with traditional aseptic manufacturing.
Deliver compliance and flexibility with a convenient, enjoyable dose form.
Improve compatibility with wider range of excipients to enhance bioavailability & stability.
Risk management to reduce the potential for iatrogenic transmission of pathogenic viruses.
Ease of administration to achieve long-term patient compliance & optimal therapeutic outcomes.
Lipid-based drug-delivery systems to assist in the delivery of poorly soluble drugs.
Reduce supply-related risks related to biosimilar product availability, cost & quality.
Perform dosage form selection in the early phases of drug development.
Chewable technology that is ideal to deliver active ingredients, without the need for water.
Potent compound handling to ensure success for complex & possibly dangerous HPAPIs.
Advanced technology platforms to enhance many biotherapeutics including ADCs.
Generating uniform site-specific ADCs utilizing a chemoenzymatic approach.
Offer new preferred benefits and improved efficacy to achieve differentiation.
Ways of increasing ADC stability and efficacy are still required for these therapies.
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
Complex, specialized requirements in micronization, to handle the toughest specifications.
The toolkit of technologies based upon lipid-based drug delivery systems.
Achieving a 40-fold increase in production of the antibody.
The cytotoxicity of HPAPIs presents handling challenges.
Choose the right technology to develop an efficient Phase I enabling drug product
Drug delivery solutions need to become more sophisticated and more effective.
in OptiMelt™ Hot Melt Extrudates for Development of Stable Final Dosage Forms
Prepared by OptiMelt™ Hot Melt Extrusion for Optimized Oral Solid Dosage Forms
An appropriate formulation often requires significant API material.
Solubility screening approaches that can save both time and money.
Scientists now have an arsenal of drug delivery techniques to choose from.
Proven and versatile particle size reduction, micronization and milling technologies
Deliver higher API concentrations in smaller capsules for patient benefits.
OptiPact™ Technology, capabilities for Orphan Drugs & Catalent's factors of differentiation.
Reduce the struggle to administer medication to animal populations.
Overcome dose acceptance and therapeutic compliance hurdles.
Macromolecule delivery by targeted delivery and enteric coating techniques.
BASF & Catalent experts discuss the development of HME oral solid dosage forms.
Macromolecules can potentially be converted from injectable to oral drug delivery.
A proven solution for improving physical stability of many oral formulations.
Discover what constitutes an Advanced Asceptic Process and the numerous advantageous.
The path to successfully marketing a biosimilar product and global regulatory environment.
Switching from small to large molecules in pharma, cell line expression and emerging markets.
The future of site-specific conjugation to improve CMC production and therapeutic index.
Innovative oral softgel platform capable of delivering multiple actives.
Learn the fundamentals of the advanced aseptic process utilizing BFS technology.
Learn about how softgel technologies can address API and processing challenges.
Learn more about integrating formulation technology in drug development.
Learn about two major changes to the USP pertaining to <231> & <661>.
BFS technology has been expanding into injectables and into biologics.
Graduate students in pharmaceutical sciences provide commentary on drug delivery topics.
Catalent continues its legacy of innovation with OptiGel Bio™ technology—expanding the versatility of softgel technology to enable the potential oral delivery of macromolecule therapies.
Developing orphan drugs to treat rare diseases is an industry priority.
How integrated development programs can be used to mitigate risk and reduce timelines.
New technology enables a brand to keep its leading market position.
RP Scherer Technology can improve timelines and commercialization potential.
We can help you bring more products to market faster and support your business objectives of driving brand growth and market share. Get to market faster with our library of non-prescription analgesic and cough, cold & allergy softgel products.
Insights in order to eliminate risk inherent to sterile manufacturing environments.
Catalent is using rational conjugate design with selective drug placement.
Learn about Orphan drug development and other fast track product development pathways.
Development of a single process configuration that reduces cost and decreases time.
This project was aimed to develop and fully validate an UPLC method.
This on-demand webinar will identify ways to determine the ideal formulation for your molecule
Catalent Schordorf has expanded controlled release and hot melt extrusion capabilities
Bioconjugates show great promise to improve existing therapeutics.
Learn more about the challenge of continuous supply available to meet clinical study needs,
Commercial success of a drug can be influenced by patient’s perception of the formulation.
Catalent worked with the client to bring a vastly superior sublingual product to market.
Creation of a custom packaging/distribution concept to meet the client’s needs.
Creation of a custom packaging and distribution solution to meet this client’s unique needs.
Identification of the impurities combined with analytical and sample handling challenges.
Case study describing custom batch manufacture of the product at a reasonable cost.
Catalent's OptiGel® Bio technology can provide a pathway for an IV to oral delivery conversion.
Patient compliance with medication can be especially challenging for pediatric populations.
Extractable and leachable detection methods and best practices.
OptiMelt™ broadly addresses bioavailability enhancement factors at any stage of drug development through commercialization, with integrated teams of scientists and technologies
SMARTag™ ADC technology enables biologic innovators to develop more efficacious antibody drug conjugates faster.
The first-ever survey investigating patient experiences with clinical trial materials
With over 75 years of experience we have the formulation expertise to tailor your API for optimal solubility, bioavailability, and permeability.
A detailed understanding of the material science of the tablet structure
Innovative biotechnology company exploring therapeutics for neuroscience indications
With our expertise and capacity across every phase of development, we offer you the peace of mind that comes from having one company manage your supply chain throughout your product’s entire lifecycle.
How Clinical Supply Management Systems can bring efficiencies to support Project Lifecycle
Global manufacturers are exploring the possibility of producing biosimilars
Bracketing, FMEA , tracking, frequency, along with the introduction of randomized media fills.
In today's enviroment solution providers are preferred over CMO's.
CMOs share their opinions on the prospects for their businesses.
An interview with Catalent's Scott Houlton.
Our new, state of the art biologics manufacturing facility—with expanded mammalian cell line engineering and biomanufacturing capabilities utilizing single-use systems—offers increased flexibility and scale to support your growth.
This presentation discusses challenges when considering LBDDS.
Specialized analytical and formulation tools aid in successful, timely Development of LBDDS.
Key considerations for selection, benefits, limitations, and future prospects.
Bend Research and Catalent enter into an agreement to provide integrated solutions.
This webcast will highlight the latest omega-3 drug developments.
This article explores importing clinical trial materials to South America.
Catalent expert Mike Jenkins explains the change Catalent's facility is making.
Explore recent advances in regards to tablet technologies.
Catalent expert interviewed at INTERPHEX 2011 about the blow/fill/seal process.
A comparison between GPEx® and traditional cell line engineering technology.
This article looks into current problems in assuring virological safety of biopharmaceuticals.
Providing a definition for virus safety is nebulous at best.
Catalent expert, Mike Merges, explores practical considerations for bioassays.
Project management is becoming more important as companies increase outsourcing.
Explore overcoming challenges in the tech transfer of biopharma products.
Catalent expert discusses how Catalent is becoming a one-stop shop for global customers.
With our broad range of experience and deep expertise, we have the talent and unique technologies to transform your concepts into excellent results.
Removal of impurities is critical in the purification process for production of final products.
Integrating quality by design into sterile manufacturing facilities is becoming more important.
As a leader in integrated services from molecule to market, we offer stability services for preclinical and clinical studies, drug registration, and commercial products.
Learn about how talent and technology can help grow a company.
This presentation focuses on improving oral delivery for poorly soluble/permeable drugs.
The process of designing, optimizing, validating and implementing your bioassay should be a transparent part of the development cycle that fast-tracks your commercial objectives—not a bottleneck
Integrated services generating fast results Catalent provides the biotechnology industry with an unparalleled range of integrated product development and testing services designed to speed your product development from bench to clinic.
Absence of evidence is not evidence of absence.
Explore the issues with technical transfer in regardss to complex pharmaceutical products
Because of the growing significance of specialty polymers, a need to fully characterize these materials for structure and purity has emerged.
Investigate the relationship between poorly-soluble drugs and disintegration time of (ODTs)
Evaluate the pharmacokinetic behavior of nanosized fenofibrate administered orally